摘要
目的探讨聚乙二醇干扰素α-2a与聚乙二醉干扰素α-2b治疗慢性乙型肝炎患者的临比疗效。方法将86例HBeAg阳性慢性乙型肝炎患者随机分为聚乙二醇干扰素α-2a治疗组46例,聚乙二醇干扰素。α-2b治疗组40例,疗程均为48周。治疗结束后随访24周。观察两组治疗12、24、36、48周及停药后24周时的生物化学、血清学及病毒学变化。结果两组病例治疗第12、24、36、48周及停药后24周时的ALT复常率、HBeAg血清学转换率比较差异无统计学意义(P>0.05),治疗第12、24、36周时的HBV DNA转阴率比较差异无统计学意义(P>0,05)。两组病例治疗第48周、停药后24周时HBV DNA转阴率分别为56.5%和35.0%(P<0.05)、58.7%和35.0%(P<0.05)。结论聚乙二醇干扰素α-2a与聚乙二醇干扰素α-2b治疗慢性乙型肝炎,于冶疗第48周、停药后24周时HBV DNA转阴率聚乙二醇干扰素α-2a治疗组高于聚乙二醇干扰素α-2b治疗组。
Objective To investigate the clinical effects between PegIFN α-2a and PegIFN α-2b in patients with chronic hepatitis B. Methods 86 patients with HBeAg-positive chronic hepatitis B were randomized to receive PegIFN α-2a （46patients ） or PegIFNα-2b （40 patients） for 48 weeks and followed up for 24 weeks. ALT normalization rate, rate of HBeAg/Anti-HBe conversion and negative conversion of HBV DNA at the 12th ,24th ,36th ,48th week after treatment and the 24th week after completion of medication were recorded and compared between the two groups. Results ALT normalization rate and rate of HBeAg/Anti- HBe conversion did not differ significantly between the two groups in treatment and follow- up （ P 〉 0. 05 ）, nor rate of negative conversion of HBV DNA at the 12th ,24th ,36th week after treatment（ P 〉 0.05 ）. Rate of negative conversion of HBV DNA was 56.5% in PeglFN α-2a treatment group and 35.0% in PeglFN α-2b treatment group at the 48th week after treatment （P〈0.05） ,and 58.7% and 35.0% at the 24＇h week after eompletion of medieation（P 〈0.05）. Conclusion In the treatment of chronic hepatitis B, rate of negative conversion of HBV DNA in PegIFN α-2a treatment group were significantly higher than those in PeglFN α-2b treatment group at the 48＇h week after treatment and the 24＇h week after completion of medication.
出处
《临床消化病杂志》
2013年第3期174-175,185,共3页
Chinese Journal of Clinical Gastroenterology
